Craig Slingluff, Jr MD

Slingluff, Jr MD, Craig L.

Primary Appointment

Professor, Surgery


  • BA, Echols Scholar, University of Virginia
  • MD, Medicine, University of Virginia School of Medicine, Charlottesville, VA
  • Fellowship, Surgical Oncology, Duke University School of Medicine, Durham, NC
  • Resident, Surgery, Duke University School of Medicine, Durham, NC

Contact Information

PO Box 800709
Clinics Building 4593
Charlottesville, VA 22908
Telephone: 434-924-9311

Research Interests

Melanoma immunobiology, Cancer Vaccines, Clinical Trials, Tumor microenvironment

Research Description

Contributions to Science

1. Identification of Class I MHC-restricted peptides recognized by cancer-reactive T-cells and testing of peptide vaccines incorporating them.
2. Development and optimization of a multipeptide vaccine inducing CD4+ helper T cell responses to melanoma.
3. T-cell retention and dysfunction at the vaccine-site microenvironment (VSME), after vaccinating with short peptides in incomplete Freund’s adjuvant (IFA), may be mediated by retention integrins.
4. Defining patterns of immune cell infiltration into the melanoma tumor microenvironment (TME) and potential barriers to immune infiltrates, and their associations with clinical outcome.
5. Identifying and characterizing the significance of tertiary lymphoid structures (TLS) in melanoma.

Links to all published work: At MyBibliography:

Current research projects:
A. Cancer vaccines using peptides combined with agonistic antibodies to costimulatory molecules CD27 and CD40, or with inhibitors of mutated BRAF.
B. Antibodies to melanoma peptides induce by vaccination and associated with improved survival.
C. Understanding the immunologic effects of vaccine adjuvants in the vaccine site microenvironment in the skin and in vaccine-draining lymph nodes
D. VITILs: Vaccine-induce tumor-infiltrating lymphocytes: using high-throughput TCR sequencing to identify T cells induced by vaccination that infiltrate melanoma metastases.
E. Focused ultrasound mediated immune therapy of cancer
F. Precision Lymph Node Dissection (PLND): Evaluating a low morbidity approach to managing patients with clinically detected melanoma metastasis isolated to one regional node. This includes genomic and gene expression studies to identify patients with just one pathologic node.
G. Barrier molecule genes and the Epidermal Differentiation Complex (EDC) genes and their roles in melanoma progression and immunobiology.
H. Retention integrins: roles of integrins CD49a, CD49b, CD103 in T cell retention in the tumor microenvironment
I. Tertiary lymphoid structures in primary desmoplastic melanoma and in melanoma metastases: understanding T cell priming in TLS and implications for clinical outcome.

Selected Publications